LinkedInXFacebook
Subscribe
Orthopedics This Week
  • My Feed
  • |Posts
  • |Events
  • |MSK Innovations
  • |Power Rankings
  • |Masterclasses
  • |Technology Awards
  • Press Releases
  • |Advertising
  • |Job Board
  • Spine
  • ◆Joints
  • ◆Upper Extremities
  • ◆Foot & Ankle
  • ◆Sports Medicine
  • ◆Pain Mgmt
  • ◆Trauma
  • ◆Biologics
  • ◆Technology
  • ◆People
  • ◆Company News
  • ◆Legal & Regulatory
Home/Legal & Regulatory and Reimbursement/Convicted Former ArthoCare CEO’s “Seating” Appeal Denied
Legal & Regulatory and Reimbursement

Convicted Former ArthoCare CEO’s “Seating” Appeal Denied

December 16, 2014 2 min read Premium comments

Advertisement

Convicted Former ArthoCare CEO’s “Seating” Appeal Denied
Courtroom Seating Chart / Source: wiki.clicklaw
Secondary

Michael Baker, the convicted and sentenced former CEO of ArthroCare Corp. told a Texas federal judge that he should have a new trial because of seating arrangements at his trial. Earlier this summer he was sentenced to 20 years in prison for committing securities fraud.

Baker’s lawyers clearly understood the famous law school lesson that when the law is against you, argue the facts. If the facts are against you, argue the law.

According to court documents, Baker and fellow convictee Michael Gluk, the company’s former CFO who was sentenced to 10 years in prison, say their families and members of the public were wrongly excluded from the courtroom so that attorneys favoring the prosecution could enjoy preferential seating. Government lawyers said their arguments were meritless.

Sixth Amendment Violation Alleged

The judge in Austin, Texas, agreed with the government lawyers and wrote on December 5, 2014, “To the extent the Baker and Gluk families were temporarily unable to find seating in the courtroom because the room was filled to capacity, no constitutional violation occurred; the Sixth Amendment requires that trials be open to the public, not that seats must be available for every person who wishes to attend.”

Law360 reported on December 8, that the defendants’ lawyers didn’t know about the family’s inability to attend jury selection during the trial. It wasn’t until Baker’s wife, Jan, realized she should have been permitted to attend the process in July. She had reportedly read an article about a New York case were a murder conviction was overturned because the defendants’ mother had been excluded from the courtroom.

The judge had wondered why the defense lawyers waited so long to complain. The judge also said that had he been aware of the family’s inability to find seats, he would have likely considered an accommodation for them.

Almost $1 Billion Losses

Advertisement

Baker and Gluk weren’t convicted of murder, but of conspiracy to commit wire and securities fraud for participating in a $400 million scheme to inflate ArthroCare’s earnings. The government says the losses to investors were in the $756 million to $958 million range. Baker was also found guilty of making false statements to the U.S. Securities and Exchange Commission. The court also ordered the two men to forfeit about $22.2 million, representing their profits from the scheme.

Another pair of former ArthroCare senior vice presidents, John Raffle and David Applegate, who pled guilty to charges related to the scheme and served as cooperating government witnesses, were sentenced to 80 months and 5 years in prison, respectively.

React:

Discussion

14
DS
Dr. Sarah MitchellOrthopedic Surgeon · Mayo Clinic

This is a fascinating development. In my practice we've seen similar outcomes with the revised protocol. The key differentiator seems to be patient selection criteria. Has anyone else noticed the correlation with BMI thresholds?

8
JT
James Thornton, MDSpine Fellow · HSS

Great point. I'd push back slightly on the conclusion, the sample size in the cited study is too small to draw population-level inferences. That said, the directional signal is compelling and worth a larger RCT.

5
RP
R. PatelSports Medicine · Stanford

We implemented a similar approach last year. Early results are promising but we're still gathering 12-month follow-up data. Happy to share our protocol if anyone is interested.

Join the conversation

Orthopedic professionals are discussing this. Sign in and upgrade to read every comment and add your voice.

Subscribe

Get Full Access

Read every OTW article and join member discussions for $24.99/month.

Get Full Access

Advertisement

Advertisement

Advertisement

Orthopedics This Week

The most trusted source in orthopedic industry news since 2005. Covering spine, joints, trauma, biologics, and the business of orthopedics.

A publication of RRY Publications, LLC

LinkedInXFacebook

Categories

  • Spine
  • Joints
  • Upper Extremities
  • Foot & Ankle
  • Sports Medicine
  • Pain Mgmt
  • Trauma
  • Biologics
  • Technology
  • People
  • Company News
  • Legal & Regulatory

Resources

  • Subscribe
  • Community Posts
  • Job Board
  • Press Release Opportunities
  • Power Rankings
  • About OTW
  • Advertise
  • Contact Us

Get Full Access

Unlimited articles, community posts, and Power Rankings.

Get Full Access

Plans start at $24.99/mo · Annual saves 20%

© 2026 Orthopedics This Week · RRY Publications, LLC

Privacy PolicyTerms of ServiceCookie Policy